Guardant Health reported second-quarter revenue of $335 million, up 44% year over year, driven by growth in oncology, biopharma, and screening segments. The company raised its full-year 2026 guidance to $1.34 billion–$1.36 billion. Oncology revenue rose 38% to $219 million, with test volume up 63%. The company received FDA approval for Guardant360 Liquid CDx, a liquid biopsy panel containing 100 times more content than its legacy product. A phased US rollout began in June. Shield testing volume reached approximately 66,000 tests. UnitedHealth's upcoming coverage is expected to expand access to about 70 million eligible Americans. A new workflow should reduce Shield's cost per test by roughly 15% by year-end. Guardant maintains its target for company-wide cash-flow breakeven by end of 2027.

Guardant Health reported second-quarter revenue of $334.98 million, marking a 44.3% increase year-over-year and exceeding analyst estimates by 6.01%. The precision oncology company posted a loss of $0.42 per share, slightly wider than the consensus estimate of $0.40. The company performed strongly in key operational metrics. Shield screening tests reached 66,000, substantially above the analyst average of 52,118. Total oncology tests performed hit 104,000, surpassing estimates of 89,203. Revenue from screening jumped 256.9% year-over-year to $52.87 million, whilst oncology revenue grew 38.1% to $219.11 million. Biopharma and data revenue increased 8.8% to $60.95 million. Guardant Health shares have declined 15.6% over the past month.

Guardant Health reported second-quarter 2026 revenue of $334.98 million, up from $232.09 million a year earlier. However, the company's net loss widened to $120.14 million, with a loss per share of $0.90. First-half 2026 sales reached $636.64 million, compared to $435.56 million in the prior year. The results highlight ongoing tension between revenue growth and profitability. The company's investment case relies on expanding adoption of blood-based cancer tests eventually supporting a path to profitability. Key risks include sustained cash burn and potential future dilution from higher spending on Shield and oncology expansion. Guardant's narrative projects $2.5 billion revenue by 2029. The most bearish analysts had assumed around $1.7 billion revenue by 2029 with continued losses.